Sanara MedTech (NASDAQ:SMTI) Stock Price Expected to Rise, HC Wainwright Analyst Says

Sanara MedTech (NASDAQ:SMTI - Get Free Report) had its price target increased by stock analysts at HC Wainwright from $50.00 to $51.00 in a report released on Wednesday, Marketbeat reports. The firm currently has a "buy" rating on the stock. HC Wainwright's target price indicates a potential upside of 68.93% from the company's current price. HC Wainwright also issued estimates for Sanara MedTech's Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.24) EPS and FY2025 earnings at ($1.12) EPS.

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $44.00 target price on shares of Sanara MedTech in a research report on Wednesday, January 22nd.

Sanara MedTech Stock Performance

Shares of SMTI stock traded down $1.03 during trading on Wednesday, reaching $30.19. 17,105 shares of the company's stock were exchanged, compared to its average volume of 23,825. The firm's fifty day moving average price is $34.26 and its 200-day moving average price is $33.74. Sanara MedTech has a twelve month low of $26.00 and a twelve month high of $39.08. The stock has a market capitalization of $268.75 million, a PE ratio of -30.49 and a beta of 1.37. The company has a quick ratio of 2.02, a current ratio of 2.23 and a debt-to-equity ratio of 0.76.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) last issued its quarterly earnings data on Tuesday, March 25th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.01. Sanara MedTech had a negative net margin of 10.71% and a negative return on equity of 19.86%. The company had revenue of $26.31 million for the quarter, compared to analyst estimates of $22.75 million. As a group, sell-side analysts anticipate that Sanara MedTech will post -1.1 EPS for the current year.

Remove Ads

Institutional Trading of Sanara MedTech

Institutional investors have recently bought and sold shares of the business. Northern Trust Corp raised its position in shares of Sanara MedTech by 0.9% in the fourth quarter. Northern Trust Corp now owns 40,816 shares of the company's stock valued at $1,355,000 after buying an additional 358 shares in the last quarter. Wells Fargo & Company MN increased its stake in Sanara MedTech by 53.9% during the 4th quarter. Wells Fargo & Company MN now owns 1,893 shares of the company's stock worth $63,000 after acquiring an additional 663 shares during the period. Barclays PLC increased its stake in Sanara MedTech by 12.1% during the 4th quarter. Barclays PLC now owns 6,423 shares of the company's stock worth $213,000 after acquiring an additional 692 shares during the period. Bank of America Corp DE raised its holdings in Sanara MedTech by 38.7% in the 4th quarter. Bank of America Corp DE now owns 3,778 shares of the company's stock valued at $125,000 after acquiring an additional 1,055 shares in the last quarter. Finally, Squarepoint Ops LLC lifted its position in shares of Sanara MedTech by 9.6% during the 4th quarter. Squarepoint Ops LLC now owns 14,822 shares of the company's stock valued at $492,000 after acquiring an additional 1,294 shares during the period. Institutional investors own 8.10% of the company's stock.

About Sanara MedTech

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.